# US 2021/0330609 A1 · Binge behavior regulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330609 A1
- Document ID: US20210330609A1
- Status: Published application
- Kind: A1
- Application number: 17/371,626
- Filed: 2021-07-09
- Published: 2021-10-28
- Earliest claimed: 2014-12-09
- Assignees: Clearmind Medicine Inc.
- Inventors: Ezekiel GOLAN
- Web page: https://patentgrep.com/patent/US20210330609A1

## CPC

- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A23L 2/52: Adding ingredients (adding preservatives A23B70/10)
- A61K 31/255: of sulfoxy acids or sulfur analogues thereof
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/36: Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- C12C 5/02: Additives for beer
- C12G 2200/21: Wine additives, e.g. flavouring or colouring agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12C: BEER; PREPARATION OF BEER BY FERMENTATION (ageing or ripening by storing C12H1/22; methods for reducing the alcohol content after fermentation C12H3/00; methods for increasing the alcohol content after fermentation C12H6/00; venting devices for casks, barrels or the like C12L9/00); PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
- C12G: WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES (beer C12C); PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H

## Abstract

Methods and compositions utilizing 2-aminoindan derivatives collectively represented by Formula I as described and defined in the specification for regulating binge behavior, particularly binge drinking, are disclosed.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method of regulating binge behavior, the method comprising administrating to a subject in need thereof a pharmaceutically acceptable salt of a compound represented by Formula I:
wherein:
each of R1 and R2 is independently selected from the group consisting of H, (C1-C8)alkyl, (C2-C4)alkenyl, (C2-C8)alkynyl, (C3-C8)cycloalkyl, aryl, heteroaryl, heteroalicyclic, —O(C1-C6) alkyl, OH, —OS(═O)2CF3, —OS(═O)2—(C1-C6)alkyl, —S(═O)R5, —CO2R5, —CONR5R6, —COR5, —CF3, CN, —SR5, —SO2NR5R6, —SO2R5, —OCO—(C1-C6)alkyl, —NCO—(C1-C6)alkyl, —CH2O—(C1-C6)alkyl, —(C1-C6)alkyl—OH, and halogen, or, alternatively, R1 and R2 together with two or more of the phenyl carbon atoms form a X1—(CR5R6)m—X2— ring, wherein each of X1 and X2 is independently selected from O, NH or S and m is 1, 2, 3, or 4;
each of R3 and R4 is independently selected from the group consisting of H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C3-C8) cycloalkyl, and —(CH2)p-thienyl, wherein p is 1, 2, 3, or 4, or alternatively, R3 and R4 are joined together to form a heterocylic ring (heteroalicyclic or heteroaryl) containing the nitrogen atom to which they are attached; and
each of R5 and R6 is independently selected from the group consisting of H, (C1-C8)alkyl, (C2-C8)alkenyl, (C3-C8)cycloalkyl and aryl,
thereby regulating the binge behavior,
wherein at least one of R3 and R4 is H, and wherein the compound of Formula I is selected from:
5-methoxy-2-aminoindan;
5,6-dimethoxy-2-aminoindan;
5-methoxy-2-(N-propylamino)indan;
5,6-dimethoxy-2-(N-propylamino)indan; 5-trifluoromethylsulfonyloxy)-2-(N-propylamino)indan;
5,6-(di-trifluoromethylsulfonyloxy)-2-(N-propylamino)Indan; and
5,6-dimethoxy-2(pyrrolidino)indan.

### Claim 24 (depends on 23)

The method of claim 23, wherein the binge behavior is associated with alcohol consumption, eating, tobacco consumption, shopping, or sexual conduct.

### Claim 25 (depends on 24)

The method of claim 24, wherein said binge behavior is binge drinking.

### Claim 26 (depends on 23)

The method of claim 23, wherein the pharmaceutically acceptable salt of the compound forms a part of a composition, which further comprises a pharmaceutically acceptable carrier.

### Claim 27 (depends on 26)

The method of claim 26, wherein the composition is in a form of a free-flowing powder, a tablet, a capsule, a lozenge, a liquid, a liquid concentrate, or a syrup.

### Claim 28 (depends on 26)

The method of claim 26, wherein the composition is a unit dosage form composition.

### Claim 29 (depends on 28)

The method of claim 28, wherein an amount of the pharmaceutically acceptable salt of the compound in the unit dosage form ranges from 30 mg to 130 mg.

### Claim 30 (depends on 29)

The method of claim 29, wherein the amount of the pharmaceutically acceptable salt of the compound is 70 mg.

### Claim 31 (depends on 23)

The method of claim 23, wherein the pharmaceutically acceptable salt of the compound is administered to the subject orally.

### Claim 32 (depends on 23)

The method of claim 23, wherein the compound is the pharmaceutically acceptable salt of 5-methoxy-2-aminoindan.

### Claim 33

A pharmaceutical composition comprising a pharmaceutically acceptable salt of 5-methoxy-2-aminoindan, the composition being formulated for oral administration, and being a liquid unit dosage form composition.

### Claim 34 (depends on 33)

The pharmaceutical composition of claim 33, being packaged as a single unit dose or as a plurality of single unit doses.

### Claim 35 (depends on 34)

The pharmaceutical composition of claim 34, wherein said unit dosage form comprises from 30 mg to 130 mg of the pharmaceutically acceptable salt of 5-methoxy-2-aminoindan.